Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
Holding FGEN?
Track your performance easily
Earnings Data
Report Date
Mar 03, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.14Last Year’s EPS
-$0.57Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: 3.63%
|Next Earnings Date:Mar 03, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook primarily driven by the robust performance of Roxadustat in China and effective cost management. However, there are challenges with decreased development revenue and uncertainties in expanding Roxadustat in new markets.Company Guidance
During the FibroGen Q3 2024 earnings call, the company provided comprehensive financial guidance and updates on strategic priorities. They reiterated full-year net product revenue guidance under U.S. GAAP to be between $135 million and $150 million, with Roxadustat net sales in China expected to range from $330 million to $350 million. FibroGen reported a strong financial position, exiting the third quarter with $160 million in cash, cash equivalents, and accounts receivable, projecting this to fund operations into 2026. Additionally, they highlighted a potential $10 million milestone payment from AstraZeneca contingent on approval for chemotherapy-induced anemia in China. The call also addressed operational cost reductions, with a significant 39% decrease in total operating expenses year-over-year, positioning FibroGen as a leaner organization focused on advancing their key pipeline assets, FG-3246 and FG-3180.Strong Performance of Roxadustat in China
Roxadustat generated $96.6 million in net sales in China, a 25% increase from Q3 2023, with a 57% increase in FibroGen's portion of net product revenue.
Financial Outlook and Guidance
FibroGen raised the bottom end of its full-year guidance for Roxadustat net sales in China to $330 million to $350 million, and expects full-year net product revenue to be between $135 million and $150 million.
Cash Management and Cost Reduction
The company ended Q3 with $160 million in cash, cash equivalents, and accounts receivable. Significant cost reductions have been implemented, reducing operating costs by 39% year-over-year.
Progress in FG-3246 and FG-3180 Programs
Positive interim results from Phase 1b study of FG-3246 in combination with enzalutamide with an rPFS of 10.2 months reported.
---
FGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $0.39 | $0.33 | -15.38% |
| Aug 06, 2024 | $0.44 | $0.46 | +4.55% |
| May 06, 2024 | $1.16 | $1.37 | +18.10% |
| Feb 26, 2024 | $1.85 | $2.12 | +14.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does FibroGen (FGEN) report earnings?
FibroGen (FGEN) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
What is FibroGen (FGEN) earnings time?
FibroGen (FGEN) earnings time is at Mar 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FGEN EPS forecast?
FGEN EPS forecast for the fiscal quarter 2024 (Q4) is -$0.14.
---